Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected.
The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)’ (Abstract #2333) was presented at ASH Annual Meeting, 10–13, December, 2022.
Questions:
- What is pegcetacoplan and what is the rationale for its use in the treatment of CAD? (0:17)
- What have clinical studies to date taught us about the efficacy and safety of pegcetacoplan in patients with CAD? (0:45)
- What were the aims, design and eligibility criteria of the CASCADE trial? (1:30)
- What are the primary and secondary endpoints of the trial, and when will data be available? (3:50)
Disclosures: Bernd Jilma is on the advisory board, speaker’s bureau and a consultant for Sanofi as well as having received grant/research support and honoraria from Sanofi.Â
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ASH 2022
Access more content on Haematology
